scholarly journals Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis

2004 ◽  
Vol 50 (7) ◽  
pp. 2327-2337 ◽  
Author(s):  
Petra Herrak ◽  
Birgit Görtz ◽  
Silvia Hayer ◽  
Kurt Redlich ◽  
Erika Reiter ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Tumor Necrosis Factor ◽  
Bone Loss ◽  
Tumor Necrosis ◽  
Necrosis Factor ◽  
Systemic Bone Loss

scholarly journals Effect of Angiotensin II on Bone Erosion and Systemic Bone Loss in Mice with Tumor Necrosis Factor-Mediated Arthritis

2020 ◽  
Vol 21 (11) ◽  
pp. 4145 ◽  
Author(s):  
Takahiko Akagi ◽  
Tomoyuki Mukai ◽  
Takafumi Mito ◽  
Kyoko Kawahara ◽  
Shoko Tsuji ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Tumor Necrosis Factor ◽  
Bone Loss ◽  
Tumor Necrosis ◽  
Bone Erosion ◽  
Joint Destruction ◽  
Bone Destruction ◽  
Ang Ii ◽  
Necrosis Factor ◽  
Systemic Bone Loss

Angiotensin II (Ang II) is the main effector peptide of the renin-angiotensin system (RAS), which regulates the cardiovascular system. The RAS is reportedly also involved in bone metabolism. The upregulation of RAS components has been shown in arthritic synovial tissues, suggesting the potential involvement of Ang II in arthritis. Accordingly, in the present study, we investigated the role of Ang II in bone erosion and systemic bone loss in arthritis. Ang II was infused by osmotic pumps in tumor necrosis factor-transgenic (TNFtg) mice. Ang II infusion did not significantly affect the severity of clinical and histological inflammation, whereas bone erosion in the inflamed joints was significantly augmented. Ang II administration did not affect the bone mass of the tibia or vertebra. To suppress endogenous Ang II, Ang II type 1 receptor (AT1R)-deficient mice were crossed with TNFtg mice. Genetic deletion of AT1R did not significantly affect inflammation, bone erosion, or systemic bone loss. These results suggest that excessive systemic activation of the RAS can be a risk factor for progressive joint destruction. Our findings indicate an important implication for the pathogenesis of inflammatory bone destruction and for the clinical use of RAS inhibitors in patients with rheumatoid arthritis.

scholarly journals Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice

2003 ◽  
Vol 48 (7) ◽  
pp. 2042-2051 ◽  
Author(s):  
Georg Schett ◽  
Kurt Redlich ◽  
Silvia Hayer ◽  
Jochen Zwerina ◽  
Brad Bolon ◽  
...  
Keyword(s):  
Tumor Necrosis Factor ◽  
Bone Loss ◽  
Transgenic Mice ◽  
Tumor Necrosis ◽  
Necrosis Factor
Sign in / Sign up

Export Citation Format

Share Document